Drug Trial Radar · NCT04330638
Treatment of COVID-19 Patients With Anti-interleukin Drugs
Last checked: Nov 20, 2026Latest source record: Mar 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
342
Actual
Start
Apr 3, 2020
Primary completion
Dec 20, 2020
Study completion May 21, 2021
Sponsor
- Lead sponsor
- University Hospital, GhentAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Belgium Health Care Knowledge Centre
- First posted
- Apr 1, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to test the safety and effectiveness of individually or simultaneously blocking IL-6 and IL-1 versus standard of care on blood oxygenation and systemic cytokine release syndrome in patients with COVID-19 coronavirus infection and acute hypoxic respiratory failure and systemic cytokine release syndrome
Conditions
- COVID-19
Interventions
Usual CareOther
Usual Care
AnakinraDrug
Anakinra will be given as a daily subcutaneous injection of 100 mg for 28 days or until hospital discharge, whichever is first
SiltuximabDrug
Siltuximab will be given via single IV infusion at a dose of 11 mg/kg
TocilizumabDrug
Tocilizumab will be given via single IV infusion at a dose of 8 mg/kg with a maximum infusion of 800 mg/injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Clinical ImprovementTime frame: at day 15
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
AZ Sint-Jan Brugge
Bruges, Belgium
University Hospital Saint-Pierre
Brussels, Belgium
Erasmus University Hospital
Brussels, Belgium
University Hospital Saint-Luc
Brussels, Belgium
University Hospital Antwerp
Edegem, Belgium
Ziekenhuis Oost-Limurg
Genk, Belgium
AZ Sint-Lucas
Ghent, Belgium
University Hospital Ghent
Ghent, Belgium
Jessa ZH
Hasselt, Belgium
University Hospital Brussels
Jette, Belgium
CHU Tivoli
La Louvière, Belgium
CHR de la Citadelle
Liège, Belgium
University Hospital Liège
Liège, Belgium
Cliniques Saint-Pierre Ottignies
Ottignies-Louvain-la-Neuve, Belgium
AZ Delta
Roeselare, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.